Clinical Trials · eu
Tedopi combinations show survival signals in lung cancer, but Phase 2 trial has not demonstrated superiority to chemotherapy
In a 106-patient trial, both Tedopi combinations had one-year survival rates above 40%. However, statistical testing compared the results against a prespecified benchmark. Whether the combinations outperform chemotherapy remains to be confirmed in larger studies.
For patients with metastatic lung cancer whose disease progresses after first-line chemotherapy combined with immunotherapy, how much the next treatment can extend survival is an important question in drug development. OSE Immunotherapeutics announced final Phase 2 results for combinations containing Tedopi (OSE2101), showing survival signals that warrant further validation but do not yet establish efficacy superior to chemotherapy.
The open-label, randomized trial, called Combi-TED, enrolled 106 patients with metastatic non-small cell lung cancer, all of whom were HLA-A2 positive and had no detected EGFR mutations or ALK or ROS1 rearrangements. Patients received Tedopi combined with the chemotherapy drug docetaxel, Tedopi combined with the immune checkpoint inhibitor nivolumab, or docetaxel alone as second-line treatment.
According to the company's announcement, one-year overall survival rates in the three groups were 47%, 46%, and 29%, respectively; median overall survival was 11.9, 11.3, and 6.4 months. Both combination groups had numerically better outcomes, but with only about 35 patients per group, considerable uncertainty remains in the estimates.
The key to interpreting the results is how the trial defined its threshold for success. Statistical testing for the primary endpoint compared each group's one-year survival rate with a prespecified benchmark of 20%, rather than directly testing differences between treatment groups. Therefore, the two Tedopi groups meeting the primary endpoint does not mean they have been proven superior to docetaxel.
A separate exploratory Bayesian analysis estimated the posterior probabilities that the two combinations improved one-year survival compared with docetaxel alone at 94.6% and 92.8%, respectively. Neither reached the trial's prespecified 95% threshold for supporting advancement to a Phase 3 study. This leaves a gap between the positive signals and a development decision that requires more evidence to bridge.
Safety also needs to be considered. The company reported no unexpected safety signals, but the rates of drug-related serious adverse events in the three groups were 17%, 24%, and 17%, respectively. In addition, the docetaxel dose used in combination with Tedopi was lower than in the monotherapy group, so subsequent comparisons must also account for differences between the treatment regimens.
The details currently available come from a company-issued summary of conference results, and full study data are still needed to help assess benefits and risks. The announcement also noted that ARTEMIA, a Phase 3 trial comparing Tedopi monotherapy with docetaxel, is ongoing. That trial will address a different treatment question and cannot directly provide the missing confirmatory evidence of efficacy for these combinations.